메뉴 건너뛰기




Volumn 5, Issue , 2015, Pages

PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

EID: 84941332095     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14035     Document Type: Article
Times cited : (36)

References (24)
  • 1
    • 84898663074 scopus 로고    scopus 로고
    • Annual report on status of cancer in China, 2010
    • Chen, W. et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 26, 48-58 (2014).
    • (2014) Chin J Cancer Res. , vol.26 , pp. 48-58
    • Chen, W.1
  • 2
    • 84897426270 scopus 로고    scopus 로고
    • A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer
    • Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F. & Barni, S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 133, 117-123 (2014).
    • (2014) Gynecol Oncol. , vol.133 , pp. 117-123
    • Lorusso, D.1    Petrelli, F.2    Coinu, A.3    Raspagliesi, F.4    Barni, S.5
  • 3
    • 84899992665 scopus 로고    scopus 로고
    • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
    • Andre, F. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 580-591 (2014).
    • (2014) Lancet Oncol. , vol.15 , pp. 580-591
    • Andre, F.1
  • 4
    • 68949102180 scopus 로고    scopus 로고
    • Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    • Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 27, 3822-3829 (2009).
    • (2009) J Clin Oncol. , vol.27 , pp. 3822-3829
    • Hess, G.1
  • 5
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1
  • 6
    • 84904724740 scopus 로고    scopus 로고
    • Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    • Mayer, I. A. et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 32, 1202-1209 (2014).
    • (2014) J Clin Oncol. , vol.32 , pp. 1202-1209
    • Mayer, I.A.1
  • 7
    • 84894231823 scopus 로고    scopus 로고
    • Landscape of genomic alterations in cervical carcinomas
    • Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
    • (2014) Nature , vol.506 , pp. 371-375
    • Ojesina, A.I.1
  • 8
    • 84924939973 scopus 로고    scopus 로고
    • Comprehensive Analysis of Targetable Oncogenic Mutations in Chinese Cervical Cancers
    • in press
    • Xiang, L. B. et al. Comprehensive Analysis of Targetable Oncogenic Mutations in Chinese Cervical Cancers. oncotarget (2015, in press).
    • Oncotarget , vol.2015
    • Xiang, L.B.1
  • 9
    • 84863338519 scopus 로고    scopus 로고
    • PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    • Janku, F. et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 30, 777-782 (2012).
    • (2012) J Clin Oncol. , vol.30 , pp. 777-782
    • Janku, F.1
  • 10
    • 84917710610 scopus 로고    scopus 로고
    • Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase i clinical experience
    • Hou, M. M. et al. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5, 11168-11179 (2014).
    • (2014) Oncotarget , vol.5 , pp. 11168-11179
    • Hou, M.M.1
  • 11
    • 84871254065 scopus 로고    scopus 로고
    • Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
    • Spoerke, J. M. et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 18, 6771-6683 (2012).
    • (2012) Clin Cancer Res. , vol.18 , pp. 6771-6783
    • Spoerke, J.M.1
  • 12
    • 84914158009 scopus 로고    scopus 로고
    • Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
    • Lopez, S. et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 135, 312-317 (2014).
    • (2014) Gynecol Oncol. , vol.135 , pp. 312-317
    • Lopez, S.1
  • 13
    • 84871968444 scopus 로고    scopus 로고
    • PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in earlyphase clinical trials
    • Janku, F. et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in earlyphase clinical trials. Cancer Res. 73, 276-284 (2013).
    • (2013) Cancer Res. , vol.73 , pp. 276-284
    • Janku, F.1
  • 14
    • 84886094737 scopus 로고    scopus 로고
    • Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix
    • Wright, A. A. et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783 (2013).
    • (2013) Cancer , vol.119 , pp. 3776-3783
    • Wright, A.A.1
  • 15
    • 84873719544 scopus 로고    scopus 로고
    • PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
    • McIntyre, J. B. et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 128, 409-414 (2013).
    • (2013) Gynecol Oncol. , vol.128 , pp. 409-414
    • McIntyre, J.B.1
  • 16
    • 79960927451 scopus 로고    scopus 로고
    • PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    • Janku, F. et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6, e22769 (2011).
    • (2011) PLoS One , vol.6 , pp. e22769
    • Janku, F.1
  • 17
    • 64549095616 scopus 로고    scopus 로고
    • Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women
    • Cui, B. et al. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol. 34, 409-416 (2009).
    • (2009) Int J Oncol. , vol.34 , pp. 409-416
    • Cui, B.1
  • 18
    • 38949121953 scopus 로고    scopus 로고
    • PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
    • Miyake, T. et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 261, 120-126 (2008).
    • (2008) Cancer Lett. , vol.261 , pp. 120-126
    • Miyake, T.1
  • 19
    • 84907208070 scopus 로고    scopus 로고
    • Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study
    • Sabine, V. S. et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32, 2951-2958 (2014).
    • (2014) J Clin Oncol , vol.32 , pp. 2951-2958
    • Sabine, V.S.1
  • 20
    • 79952713255 scopus 로고    scopus 로고
    • A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas
    • Rudd, M. L. et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 17, 1331-1340 (2011).
    • (2011) Clin Cancer Res. , vol.17 , pp. 1331-1340
    • Rudd, M.L.1
  • 21
    • 84941245510 scopus 로고    scopus 로고
    • PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy + /- Cetuximab in Cervical Cancer Patients
    • de la Rochefordiere, A. et al. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy + /- Cetuximab in Cervical Cancer Patients. Clin Cancer Res 21, 2530-2537 (2015).
    • (2015) Clin Cancer Res , vol.21 , pp. 2530-2537
    • De La Rochefordiere, A.1
  • 22
    • 0035872199 scopus 로고    scopus 로고
    • Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
    • Brognard, J. et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61, 3986-3997 (2001).
    • (2001) Cancer Res , vol.61 , pp. 3986-3997
    • Brognard, J.1
  • 23
    • 31544444486 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines
    • Lee, C. M. et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 12, 250-25 (2006).
    • (2006) Clin Cancer Res , vol.12 , pp. 250-325
    • Lee, C.M.1
  • 24
    • 84907208070 scopus 로고    scopus 로고
    • Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study
    • Sabine, V. S. et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32, 2951-2958 (2014).
    • (2014) J Clin Oncol , vol.32 , pp. 2951-2958
    • Sabine, V.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.